TW200744675A - Drug-surfactant complexes for sustained release - Google Patents

Drug-surfactant complexes for sustained release

Info

Publication number
TW200744675A
TW200744675A TW095130300A TW95130300A TW200744675A TW 200744675 A TW200744675 A TW 200744675A TW 095130300 A TW095130300 A TW 095130300A TW 95130300 A TW95130300 A TW 95130300A TW 200744675 A TW200744675 A TW 200744675A
Authority
TW
Taiwan
Prior art keywords
release
sustained
complexes
surfactant
ionic
Prior art date
Application number
TW095130300A
Other languages
English (en)
Inventor
Cherng-Ju Kim
Original Assignee
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas filed Critical Univ Arkansas
Publication of TW200744675A publication Critical patent/TW200744675A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095130300A 2005-08-17 2006-08-17 Drug-surfactant complexes for sustained release TW200744675A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/207,126 US20070042041A1 (en) 2005-08-17 2005-08-17 Drug-surfactant complexes for sustained release

Publications (1)

Publication Number Publication Date
TW200744675A true TW200744675A (en) 2007-12-16

Family

ID=37758400

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095130300A TW200744675A (en) 2005-08-17 2006-08-17 Drug-surfactant complexes for sustained release

Country Status (7)

Country Link
US (2) US20070042041A1 (zh)
EP (1) EP1915138A4 (zh)
KR (1) KR20080047389A (zh)
AU (1) AU2006279441A1 (zh)
CA (1) CA2618076A1 (zh)
TW (1) TW200744675A (zh)
WO (1) WO2007022356A2 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923836A2 (pt) 2008-12-31 2015-07-21 Upsher Smith Lab Inc Composições farmacêuticas orais contendo opióide e métodos
BR112012008317A2 (pt) 2009-09-17 2016-03-22 Upsher Smith Lab Inc produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
CA2804147A1 (en) * 2010-06-30 2012-01-05 Upsher-Smith Laboratories, Inc. Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
WO2013017388A1 (de) * 2011-07-29 2013-02-07 Basf Se Poröses stärkegranulat enthaltend ein anionisches oder kationisches pestizid und ein kationische oder anionische matrix
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
EP3131546B1 (en) * 2014-04-16 2022-02-16 Rapamycin Holdings, Inc. Oral rapamycin preparation for use in treating feline chronic gingivo- stomatitis (fcgs)
SG11201802777XA (en) 2015-10-14 2018-05-30 X Therma Inc Compositions and methods for reducing ice crystal formation
CN108295642B (zh) * 2018-03-18 2021-11-30 国润生物科技（深圳）有限公司 一种高效去除含硫污染气体型空气净化剂组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
NL297631A (zh) * 1963-06-03
FR1396710A (fr) * 1964-06-15 1965-04-23 Diwag Chemische Fabriken G M B Procédé pour la fabrication de charges ou supports perfectionnés et produits obtenus
US3577514A (en) * 1968-06-10 1971-05-04 Pfizer Sustained release pharmaceutical tablets
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
CA2259418A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
CA2316539C (en) * 1997-12-26 2008-11-18 Yamanouchi Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
US6896519B2 (en) * 1998-07-27 2005-05-24 Chen & Chen, Llc Method of oral transmucosal delivery of a therapeutic agent
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
CA2389304A1 (en) * 1999-11-01 2001-05-10 Corinne S. Lengsfeld Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
AU2003258075A1 (en) * 2002-08-06 2004-02-23 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
AU2004275835B2 (en) * 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release

Also Published As

Publication number Publication date
KR20080047389A (ko) 2008-05-28
WO2007022356A3 (en) 2007-11-15
EP1915138A2 (en) 2008-04-30
US20070042041A1 (en) 2007-02-22
EP1915138A4 (en) 2013-01-02
US20100105637A1 (en) 2010-04-29
CA2618076A1 (en) 2007-02-22
WO2007022356A2 (en) 2007-02-22
AU2006279441A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
TW200744675A (en) Drug-surfactant complexes for sustained release
MXPA05007328A (es) Composiciones que contienen agentes antiacne y el uso de las mismas.
AR063466A1 (es) Composiciones detergentes espesadas por agentes tensioactivos que comprenden microfibras de celulosa y sus metodos de preparacion
TW200642694A (en) Anti-M-CSF antibody compositions
MX2009002547A (es) Composiciones terapeuticas de peptido de fusion.
TW200643156A (en) Aqueous dispersant for chemical polishing, chemical polishing method, and kit used in preparation of aqueous dispersant for chemical polishing
WO2007011884A3 (en) Dough compositions for extended shelf life baked articles
WO2010138837A3 (en) Nanodiamond particle complexes
WO2006023591A8 (en) Enhanced oil delivery from structured surfactant formulations
MX348936B (es) Formulaciones de antibioticos, dosis unitarias, equipos y metodos.
TW200738283A (en) Formulations of conjugated estrogens and bazedoxifene
WO2007035596A3 (en) Metal organic framework odor sequestration and fragrance delivery
MY151071A (en) Low-foaming preparations for crop protection
AU2009296340B2 (en) Glyphosate formulations containing amidoalkylamine surfactants
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
CY1112980T1 (el) Φαρμακευτικες συνθεσεις, οι οποιες διαθετουν βελτιωμενα προφιλ διαλυσης για δυσδιαλυτες δραστικες ουσιες
EA200900267A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ
WO2008105916A3 (en) Dissociating agents, formulations and methods providing enhanced solubility of fluorides
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
MY150971A (en) Mineral amino acid polysaccharide complex
MY151470A (en) Controlled release solid preparation
MX2009008542A (es) Agentes de suministro de acido fenilalquilcarboxilico.
WO2009141548A3 (fr) Composition et procede pour la destruction de polluants organophosphores et/ou organosoufres
TW200738284A (en) Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a pH modifier
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments